文章：

用于CAR T细胞临床前评估的同基因小鼠模型

Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells

原文发布日期：18 September 2024

DOI: 10.3390/cancers16183186

类型: Article

开放获取: 是

英文摘要：

Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of hematological malignancies. Unfortunately, this improvement has yet to be translated into the solid tumor field. Current immunodeficient models used in pre-clinical testing often overestimate the efficacy of CAR T cell therapy as they fail to recapitulate the immunosuppressive tumor microenvironment characteristic of solid tumors. As CAR T cell monotherapy is unlikely to be curative for many solid tumors, combination therapies must be investigated, for example, stromal remodeling agents and immunomodulators. The evaluation of these combination therapies requires a fully immunocompetent mouse model in order to recapitulate the interaction between the host’s immune system and the CAR T cells. This review will discuss the need for improved immunocompetent murine models for the pre-clinical evaluation of CAR T cells, the current use of such models and future directions.

摘要翻译： 

嵌合抗原受体（CAR）T细胞疗法已彻底改变了血液系统恶性肿瘤的治疗格局。然而，这一进展尚未在实体瘤领域实现同等突破。当前临床前研究采用的免疫缺陷模型常高估CAR-T细胞疗法的疗效，因其无法模拟实体瘤特有的免疫抑制性肿瘤微环境。鉴于CAR-T细胞单药疗法难以治愈多数实体瘤，必须探索联合治疗策略，例如基质重塑剂与免疫调节剂的组合应用。评估此类联合疗法需要建立完全免疫健全的小鼠模型，以重现宿主免疫系统与CAR-T细胞间的相互作用。本综述将探讨改进免疫健全小鼠模型对CAR-T细胞临床前评价的必要性，分析现有模型的应用现状，并展望未来发展方向。

原文链接：

Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells